This study focuses on testing a new treatment called WEF-001 for people with advanced solid tumors that have a specific change in their KRAS gene. The goal is to understand how safe and tolerable this treatment is and to see how it behaves in the body. This research is important because KRAS mutations are challenging to treat, and finding effective therapies could greatly improve outcomes for patients dealing with these types of cancers. Participants in this study will receive WEF-001 as a single treatment. Researchers will observe how the drug is processed in the body and will monitor any potential side effects. The study also aims to gather early data on how well the treatment might work against the cancer. By focusing on safety and how the drug interacts with the body, the study aims to lay the groundwork for future research that could lead to better treatment options for patients with these difficult-to-treat tumors.
Inclusion Criteria: * Advanced KRAS-mutant solid tumor: pancreatic ductal adenocarcinoma, colorectal cancer, non small cell lung cancer, platinum-resistant serous ovarian cancer, cholangiocarcinoma or urothelial bladder cancer * Progressive disease following at least one line of standard of care therapy * Measurable disease as defined by RECIST v1.1 * ECOG ≤ 1 Exclusion Criteria: * Active systemic infection requiring anti-infective therapy within 28 days prior to first dose of IMP * Active cardiovascular disease * Having a second active primary malignancy, requiring systemic administration of any cancer-related therapy * Liver dysfunction * Untreated brain metastasis and/or unstable neurological dysfunction * Inflammatory bowel disease * Active and untreated hyperthyroidism * Lupus erythematosus within past 5 years
is designated in this study